A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Neoplasm Metastasis
DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Trastuzumab Emtansine|DRUG: Atezolizumab
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Baseline up to 30 days after last dose of study drug administration (up to approximately 14 years)|Percentage of Participants With Adverse Events Leading to Study Treatment Discontinuation or Dose Reduction, Baseline up to 30 days after last dose of study drug administration (up to approximately 14 years)
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.